NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether XBiotech, Inc. (“XBiotech”) (NASDAQ:XBIT) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/XBIT-Info-Request-Form-1034. There is no cost or obligation to you.
On April 20, 2017, XBiotech announced that the European Medicines Agency (“EMA”) had rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech's candidate antibody for the treatment of colorectal cancer. Then on May 18, 2017, XBiotech announced it had received a negative opinion for its MAA. Then on June 9, 2017, XBiotech announced it had discontinued a Phase 3 study for the treatment after the findings “were not sufficient to meet efficacy or the threshold for continuation.”
To learn more about the investigation of XBiotech contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/XBIT-Info-Request-Form-1034.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
